Texas Bank & Trust Co Buys Shares of 1,600 Charles River Laboratories International, Inc. (NYSE:CRL)

Texas Bank & Trust Co bought a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,600 shares of the medical research company’s stock, valued at approximately $295,000.

A number of other institutional investors also recently bought and sold shares of the company. Cornerstone Investment Partners LLC lifted its holdings in Charles River Laboratories International by 3.7% in the fourth quarter. Cornerstone Investment Partners LLC now owns 1,940 shares of the medical research company’s stock valued at $358,000 after acquiring an additional 69 shares during the period. Metis Global Partners LLC increased its position in Charles River Laboratories International by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 1,720 shares of the medical research company’s stock worth $318,000 after buying an additional 72 shares in the last quarter. Two Sigma Securities LLC increased its position in Charles River Laboratories International by 4.3% in the fourth quarter. Two Sigma Securities LLC now owns 1,981 shares of the medical research company’s stock worth $366,000 after buying an additional 81 shares in the last quarter. Wahed Invest LLC increased its position in Charles River Laboratories International by 6.5% in the fourth quarter. Wahed Invest LLC now owns 1,321 shares of the medical research company’s stock worth $244,000 after buying an additional 81 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its position in Charles River Laboratories International by 16.3% in the fourth quarter. Jones Financial Companies Lllp now owns 641 shares of the medical research company’s stock worth $118,000 after buying an additional 90 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CRL. Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and upped their price target for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Redburn Atlantic upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price target for the company in a research report on Monday, March 3rd. Cowen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Wednesday. Evercore ISI upgraded Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 price target for the company in a research report on Thursday, May 8th. Finally, Barclays upped their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $172.31.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO James C. Foster acquired 6,075 shares of the stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. The trade was a 3.42% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 5,040 shares of company stock worth $807,407 in the last quarter. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $141.00 on Monday. The stock has a market capitalization of $6.93 billion, a P/E ratio of 940.00, a P/E/G ratio of 4.54 and a beta of 1.50. The stock has a 50-day moving average price of $135.43 and a 200 day moving average price of $164.76. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analysts’ expectations of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $2.27 EPS. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).